Hide metadata

dc.date.accessioned2022-03-31T15:17:09Z
dc.date.available2022-03-31T15:17:09Z
dc.date.created2021-08-16T16:00:36Z
dc.date.issued2021
dc.identifier.citationZiouti, Fani Rummler, Maximilian Steyn, Beatrice Thiele, Tobias Seliger, Anne Duda, Georg N. Bogen, Bjarne Willie, Bettina M. Jundt, Franziska . Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton’s Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease. International Journal of Molecular Sciences. 2021, 22:3840(8), 1-14
dc.identifier.urihttp://hdl.handle.net/10852/93119
dc.description.abstractLimiting bone resorption and regenerating bone tissue are treatment goals in myeloma bone disease (MMBD). Physical stimuli such as mechanical loading prevent bone destruction and enhance bone mass in the MOPC315.BM.Luc model of MMBD. It is unknown whether treatment with the Bruton’s tyrosine kinase inhibitor CC-292 (spebrutinib), which regulates osteoclast differentiation and function, augments the anabolic effect of mechanical loading. CC-292 was administered alone and in combination with axial compressive tibial loading in the MOPC315.BM.Luc model for three weeks. However, neither CC-292 alone nor its use in combination with mechanical loading was more effective in reducing osteolytic bone disease or rescuing bone mass than mechanical stimuli alone, as evidenced by microcomputed tomography (microCT) and histomorphometric analysis. Further studies are needed to investigate novel anti-myeloma and anti-resorptive strategies in combination with physical stimuli to improve treatment of MMBD.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titlePrevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton’s Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
dc.typeJournal article
dc.creator.authorZiouti, Fani
dc.creator.authorRummler, Maximilian
dc.creator.authorSteyn, Beatrice
dc.creator.authorThiele, Tobias
dc.creator.authorSeliger, Anne
dc.creator.authorDuda, Georg N.
dc.creator.authorBogen, Bjarne
dc.creator.authorWillie, Bettina M.
dc.creator.authorJundt, Franziska
cristin.unitcode185,53,18,12
cristin.unitnameAvdeling for immunologi og transfusjonsmedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1926422
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International Journal of Molecular Sciences&rft.volume=22:3840&rft.spage=1&rft.date=2021
dc.identifier.jtitleInternational Journal of Molecular Sciences
dc.identifier.volume22
dc.identifier.issue8
dc.identifier.doihttps://doi.org/10.3390/ijms22083840
dc.identifier.urnURN:NBN:no-95710
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1422-0067
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/93119/1/Postnr%2B1926422_Ziouti%2Bet%2Bal_Int%2BJ%2BMolec%2BSci-22-03840-v2.pdf
dc.type.versionPublishedVersion
cristin.articleid3840


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International